Compare CRSP & ALK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSP | ALK |
|---|---|---|
| Founded | 2013 | 1932 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Air Freight/Delivery Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 4.9B |
| IPO Year | 2016 | 2003 |
| Metric | CRSP | ALK |
|---|---|---|
| Price | $55.44 | $39.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 16 |
| Target Price | ★ $87.56 | $57.91 |
| AVG Volume (30 Days) | 1.3M | ★ 2.4M |
| Earning Date | 11-09-2026 | 10-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $289,590,000.00 | ★ $10,426,000,000.00 |
| Revenue This Year | $1,063.30 | $10.99 |
| Revenue Next Year | $283.48 | $8.02 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9169.85 | 8.09 |
| 52 Week Low | $44.12 | $33.03 |
| 52 Week High | $78.48 | $60.63 |
| Indicator | CRSP | ALK |
|---|---|---|
| Relative Strength Index (RSI) | 52.39 | 38.66 |
| Support Level | $50.56 | $36.30 |
| Resistance Level | $60.04 | $41.36 |
| Average True Range (ATR) | 2.83 | 1.42 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 51.06 | 6.20 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Alaska Air Group Inc operates two airlines, Alaska and Horizon, in three operating segments. The Alaska Airlines segment includes scheduled air transportation on Alaska's Boeing and Airbus jet aircraft for passengers and cargo throughout the U.S., and in parts of Mexico and Costa Rica. The Regional segment includes Horizon's and other third-party carriers' scheduled air transportation for passengers across a shorter distance network within the U.S. and Canada under capacity purchase agreements. The Hawaiian Airlines segment includes scheduled air transportation on Hawaiian's Boeing and Airbus aircraft for passengers and cargo. It earns revenues from Passenger tickets, including ticket breakage and net of taxes and fees, Passenger ancillary, and Mileage Plan passenger revenue.